肿瘤放射药物科学的最新进展和即将面临的挑战。
Recent advances and impending challenges for the radiopharmaceutical sciences in oncology.
机构信息
Departments of Radiology and Chemistry, O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, AL, USA.
Department of Radiology, University of Michigan, Ann Arbor, MI, USA.
出版信息
Lancet Oncol. 2024 Jun;25(6):e236-e249. doi: 10.1016/S1470-2045(24)00030-5.
Abstract
This paper is the first of a Series on theranostics that summarises the current landscape of the radiopharmaceutical sciences as they pertain to oncology. In this Series paper, we describe exciting developments in radiochemistry and the production of radionuclides, the development and translation of theranostics, and the application of artificial intelligence to our field. These developments are catalysing growth in the use of radiopharmaceuticals to the benefit of patients worldwide. We also highlight some of the key issues to be addressed in the coming years to realise the full potential of radiopharmaceuticals to treat cancer.
摘要
这篇论文是关于放射性药物治疗学的一系列论文中的第一篇，总结了当前放射药物科学在肿瘤学中的现状。在本系列论文中，我们描述了放射化学和放射性核素生产方面令人兴奋的发展，治疗学的开发和转化，以及人工智能在我们领域的应用。这些发展正在促进放射性药物的使用，使全世界的患者受益。我们还强调了未来几年需要解决的一些关键问题，以充分发挥放射性药物治疗癌症的潜力。
相似文献
1
Recent advances and impending challenges for the radiopharmaceutical sciences in oncology.
Lancet Oncol. 2024 Jun;25(6):e236-e249. doi: 10.1016/S1470-2045(24)00030-5.
2
Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics.
Lancet Oncol. 2024 Jun;25(6):e250-e259. doi: 10.1016/S1470-2045(24)00037-8.
3
Chemistry Considerations for the Clinical Translation of Oncology PET Radiopharmaceuticals.
Mol Pharm. 2020 Jul 6;17(7):2245-2259. doi: 10.1021/acs.molpharmaceut.0c00328. Epub 2020 Jun 5.
4
Role of Machine Learning and Artificial Intelligence in Interventional Oncology.
Curr Oncol Rep. 2021 Apr 20;23(6):70. doi: 10.1007/s11912-021-01054-6.
5
Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer.
Curr Med Chem. 2020;27(41):7003-7031. doi: 10.2174/0929867327999200727190423.
6
Bifunctional chelators in the design and application of radiopharmaceuticals for oncological diseases.
Curr Med Chem. 2012;19(17):2667-88. doi: 10.2174/092986712800609751.
7
Moving Forward in the Next Decade: Radiation Oncology Sciences for Patient-Centered Cancer Care.
JNCI Cancer Spectr. 2021 May 17;5(4). doi: 10.1093/jncics/pkab046. eCollection 2021 Aug.
8
Artificial intelligence for clinical oncology.
Cancer Cell. 2021 Jul 12;39(7):916-927. doi: 10.1016/j.ccell.2021.04.002. Epub 2021 Apr 29.
9
Role of Artificial Intelligence in Theranostics:: Toward Routine Personalized Radiopharmaceutical Therapies.
PET Clin. 2021 Oct;16(4):627-641. doi: 10.1016/j.cpet.2021.06.002.
10
National Cancer Institute Programmatic Collaboration for Investigational Radiopharmaceuticals.
Am Soc Clin Oncol Educ Book. 2018 May 23;38:488-494. doi: 10.1200/EDBK_200199.
引用本文的文献
1
MIB guides: [Zr]Zr-DFO-trastuzumab and [Cu]Cu-NOTA-Trastuzumab for Preclinical Cancer Imaging.
Mol Imaging Biol. 2025 Jun 26. doi: 10.1007/s11307-025-02022-3.
2
Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells.
Theranostics. 2025 May 25;15(13):6497-6515. doi: 10.7150/thno.113354. eCollection 2025.
3
Copper-mediated radiochemistry: historical impact, current trends, and future possibilities.
Npj Imaging. 2025 Jun 10;3:25. doi: 10.1038/s44303-025-00087-x. eCollection 2025.
4
Novel treatment approaches utilizing antibody-drug conjugates in breast cancer.
NPJ Breast Cancer. 2025 May 13;11(1):42. doi: 10.1038/s41523-025-00743-w.
5
Patent spotlight on theranostics targeting fibroblast activation protein for personalized cancer care.
Pharm Pat Anal. 2024;13(4-6):149-160. doi: 10.1080/20468954.2025.2500811. Epub 2025 May 6.
6
Identifying new therapeutics for focused ultrasound-enhanced drug delivery in the management of glioblastoma.
Front Oncol. 2025 Mar 13;15:1507940. doi: 10.3389/fonc.2025.1507940. eCollection 2025.
7
First-in-human study of an optimized, potential kit-type, SSTR antagonist Ga-DATA-LM4 in patients with metastatic neuroendocrine tumors.
Theranostics. 2025 Jan 20;15(6):2510-2522. doi: 10.7150/thno.94521. eCollection 2025.
8
Improvement of End-of-Synthesis Radiochemical Purity of Lu-DOTA-PSMA-Ligands with Alternative Synthesis Approaches: Conversion Upswing and Side-Products Minimization.
Pharmaceutics. 2024 Nov 30;16(12):1535. doi: 10.3390/pharmaceutics16121535.
9
Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy.
Ther Adv Med Oncol. 2025 Jan 2;17:17588359241309461. doi: 10.1177/17588359241309461. eCollection 2025.
10
Advances and challenges in precision imaging.
Lancet Oncol. 2025 Jan;26(1):e34-e45. doi: 10.1016/S1470-2045(24)00395-4.
本文引用的文献
1
Radiochemistry: A Hot Field with Opportunities for Cool Chemistry.
ACS Cent Sci. 2023 Nov 14;9(12):2183-2195. doi: 10.1021/acscentsci.3c01050. eCollection 2023 Dec 27.
2
Chemokine Receptor CXCR4 Radioligand Targeted Therapy Using 177Lutetium-pentixather for Pulmonary Neuroendocrine Cancers.
Radiat Res. 2024 Jan 1;201(1):35-47. doi: 10.1667/RADE-23-00064.1.
3
Production, isolation, and shipment of clinically relevant quantities of astatine-211: A simple and efficient approach to increasing supply.
Nucl Med Biol. 2023 Nov-Dec;126-127:108387. doi: 10.1016/j.nucmedbio.2023.108387. Epub 2023 Sep 21.
4
Applications of Artificial Intelligence in PSMA PET/CT for Prostate Cancer Imaging.
Semin Nucl Med. 2024 Jan;54(1):141-149. doi: 10.1053/j.semnuclmed.2023.06.001. Epub 2023 Jun 23.
5
Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists.
Front Med (Lausanne). 2022 Dec 7;9:1034315. doi: 10.3389/fmed.2022.1034315. eCollection 2022.
6
EANM practice guideline for quantitative SPECT-CT.
Eur J Nucl Med Mol Imaging. 2023 Mar;50(4):980-995. doi: 10.1007/s00259-022-06028-9. Epub 2022 Dec 5.
7
PSMA Expression in Solid Tumors beyond the Prostate Gland: Ready for Theranostic Applications?
J Clin Med. 2022 Nov 7;11(21):6590. doi: 10.3390/jcm11216590.
8
The Future of Targeted α-Therapy Is Bright, but Rigorous Studies Are Necessary to Advance the Field.
J Nucl Med. 2023 Feb;64(2):219-220. doi: 10.2967/jnumed.122.264805. Epub 2022 Oct 20.
9
From Automated Synthesis to In Vivo Application in Multiple Types of Cancer-Clinical Results with [Ga]Ga-DATA.SA.FAPi.
Pharmaceuticals (Basel). 2022 Aug 14;15(8):1000. doi: 10.3390/ph15081000.
10
Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with Lu-PSMA and Combined Ac- and Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation.
Diagnostics (Basel). 2022 Aug 10;12(8):1926. doi: 10.3390/diagnostics12081926.
Zotero 插件